Table 3.
Two-Way Sensitivity Analysis. Unfractionated Heparin (UH), Low-Molecular-Weight Heparin (LMWH), and Selective UH/LMWH
| Estimates per 1,000 Patients Treated | Treated at Home (%) | Relative Risk of Recurrent Thromboembolism at 3 Months, LMWH vs UH | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1 | 1.1 | 1.2 | ||
| Cost of treatment (thousands), $ | |||||||||
| UH | 0 | 3,203 | 3,203 | 3,203 | 3,203 | 3,203 | 3,203 | 3,203 | 3,203 |
| LMWH | 70 | 2,505 | 2,519 | 2,533 | 2,547 | 2,561 | 2,575 | 2,588 | 2,602 |
| 40* | 2,854 | 2,870 | 2,886 | 2,902 | 2,918 | 2,934 | 2,950 | 2,966 | |
| 20 | 3,087 | 3,105 | 3,122 | 3,139 | 3,156 | 3,173 | 3,191 | 3,208 | |
| 10 | 3,204 | 3,222 | 3,240 | 3,257 | 3,275 | 3,293 | 3,311 | 3,329 | |
| Selective UH/LMWH | 70 | 2,470 | 2,478 | 2,487 | 2,495 | 2,503 | 2,512 | 2,520 | 2,528 |
| 40* | 2,784 | 2,789 | 2,794 | 2,799 | 2,803 | 2,808 | 2,813 | 2,818 | |
| 20 | 2,994 | 2,996 | 2,999 | 3,001 | 3,003 | 3,006 | 3,008 | 3,010 | |
| 10 | 3,099 | 3,100 | 3,101 | 3,102 | 3,103 | 3,105 | 3,106 | 3,107 | |
| Recurrent Thromboembolism, n | |||||||||
| UH | 0 | 61 | 61 | 61 | 61 | 61 | 61 | 61 | 61 |
| LMWH | 0–70 | 30 | 36 | 42 | 48 | 54 | 60 | 67 | 73 |
| Selective UH/LMWH | 40* | 49 | 51 | 54 | 56 | 59 | 61 | 63 | 66 |
| Mortality, n | |||||||||
| UH | 0 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| LMWH | 0–70 | 3 | 4 | 4 | 5 | 5 | 6 | 6 | 7 |
| Selective UH/LMWH | 40* | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 |
*
Base-case assumptions.